Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CFB | P00751 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929008 | 0.93 | LMNA (0.41) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929105 | 0.93 | LMNA (0.40) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929241 | 0.90 | KDM4E (0.39) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929076 | 0.90 | CFB (0.41) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929204 | 0.89 | LMNA (0.39) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5928958 | 0.88 | LMNA (0.43) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929316 | 0.88 | ALDH1A1 (0.40) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5928984 | 0.88 | ALDH1A1 (0.41) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5928973 | 0.88 | KMT2A (0.39) | LMNAKMT2AMEN1CFBALDH1A1 | |
| SCHEMBL5929207 | 0.87 | CFB (0.41) | LMNAKMT2AMEN1CFBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | LMNA 4776/4885KMT2A 2955/4885MEN1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.